?Accent Therapeutics, Inc. will present new data from lead programs ATX-559 (a first-in-class oral DHX9 inhibitor) and ATX-295 (a novel KIF18A inhibitor) at the upcoming?American Association for Cancer Research?(AACR) annual meeting in late April.? Check out their?poster presentation, sharing new preclinical data for ATX-559 on April 28, 9 AM - 12 PM, and join their?oral presentation?on ATX-295, discussing robust, selective activity in ovarian cancer models later that day, 2:30 PM - 4:30 PM. #AACR25 Learn more in the press release here:?https://lnkd.in/eB_-bPdK??
The Column Group
风险投资与私募股权管理人
San Francisco，CA 5,285 位关注者
Cultivating new frontiers of science into successful ventures and unprecedented therapeutic breakthroughs.
关于我们
The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics.
TCG’s investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later stage, single product-orientated companies across multiple industry sectors, with proximity to value inflection points and the early identification of a Pharma “buyer” as key investment considerations.
In contrast, TCG takes the long view in making investments, recognizing that significant time is often required to generate significant value. Our approach is not “building-to-exit.” Key variables, including scientific opportunities, the competitive and regulatory landscape, and Pharma priorities, can change very rapidly. Instead, TCG’s mission is the generation of fundamentally strong companies, built from the ground up based on great science and the ability to generate multiple differentiated product opportunities.
Rather than diversification, TCG emphasizes focus. We are dedicated to early stage drug discovery as the best source of a new generation of novel, highly effective human therapies. We believe that the most critical resources, such as great ideas, world class founders, and top quality managerial and scientific talent, are very rare and that concentrating them within a small cohort of companies is the key path to success.
TCG is about the bold pursuit of big ideas using innovative science to generate breakthrough therapies that address significant diseases. Our firm is committed to all facets of company building and brings together a rich combination of scientific, financial and operational expertise to shape promising science into a value-rich portfolio poised to have a profound impact on human health.
- 网站
-
https://www.thecolumngroup.com
The Column Group的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 11-50 人
- 总部
- San Francisco，CA
- 类型
- 私人持股
地点
-
主要
获取路线
US，CA，San Francisco
The Column Group员工
动态
-
Remix Therapeutics?will have a poster presentation at the American Association for Cancer Research annual meeting?April 28, 2025, demonstrating preclinical anti-tumor activity of REM-422 in adenoid cystic carcinoma (ACC) and acute myeloid leukemia (AML). #AACR25 View abstract in advance here:?https://lnkd.in/g_QJMWrV?
-
-
Congratulations to?Tenaya Therapeutics?on the publication of positive preclinical data in?Nature Communications,?supporting the potential of TN-201 as a novel gene therapy treatment for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM). Preclinical data demonstrates enhanced cardiac function and survival in MYBPC3 cardiomyopathy mouse models, paving the way for Tenaya’s clinical development plan.? ? Read the press release:?https://lnkd.in/gazYJ8VZ Read the Nature Portfolio?publication:? https://lnkd.in/gg4-ipPG? #GeneTherapy #HeartDisease?
-
-
Exciting news!?Tenaya Therapeutics?announced a late breaking oral presentation from the?MyPEAK?-1 Phase 1b/2 clinical trial of TN-201 at the upcoming American College of Cardiology’s Annual Scientific Session. New data from Cohort 1 will be presented by?Milind Desai MD MBA.?TN-201 is under development for MYBPC3-associated hypertrophic cardiomyopathy (HCM).? Congratulations to CEO Faraz Ali?and to the entire Tenaya Therapeutics team—check it out at ACC on March 31st?in Chicago!? Read the press release here:?https://lnkd.in/gnUgmGWB ? #ACC25?#GeneTherapy?#HeartHealth?
-
-
Big news from?Kimia Therapeutics—Imran Haque, Ph.D., steps into the role of Chief Technology Officer. Dr. Haque joins Kimia's executive team and will lead the development of Kimia’s ATLAS (AcTive Learning with Automated Synthesis and screening) technology platform. Congratulations, Dr. Haque and Kimia Therapeutics! Read the press release here:?https://lnkd.in/gWurGJi8
-
-
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update https://lnkd.in/g2-krZ5E
-
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results https://lnkd.in/gtF6xTET
-
Tenaya Therapeutics Announces Pricing of Public Offering https://lnkd.in/gK8CwH7Y
-
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline https://lnkd.in/gPKhDcBe
-
ORIC??Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones https://lnkd.in/gDaKPgTn